Zydus Lifesciences receives final nod from the USFDA for Ivermectin Cream

Zydus Lifesciences receives final nod from the USFDA for Ivermectin Cream

by admin- Thursday, August 4th, 2022 04:04:39 PM

Zydus Lifesciences obtained very last approval from the US Food and Drug Administration (USFDA) to marketplace Ivermectin Cream, 1%. USRLD: Soolantra.

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea. The drug will be synthetic at the organization’s topical manufacturing facility at Ahmedabad, India.

Ivermectin Cream had annual income of USD 176 million in the United States in keeping with IQVIA facts.

News Updates